Woodline Partners »

Oruka Therapeutics shares owned by Woodline Partners

Quarter-by-quarter ownership of Oruka Therapeutics shares owned by Woodline Partners from 13F filings

Historical chart of Woodline Partners investment in Oruka Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Oruka Therapeutics held by Woodline Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Oruka Therapeutics by Woodline Partners

Quarter filed Position value Share count Share price at filing
2024-09-30 $9.6M 391k 24.51

More positions owned by Woodline Partners

Meta Platforms Cl A (META)
Gilead Sciences (GILD)
Abbvie (ABBV)
Revolution Medicines (RVMD)
Vaxcyte (PCVX)
Asml Holding N V N Y Registry Shs (ASML)
Nuvalent Inc-a (NUVL)
Permian Resources Corp Class A Com (PR)
Encana Corporation (OVV)
Keysight Technologies (KEYS)
Danaher Corporation (DHR)
Aon Shs Cl A (AON)
Stmicroelectronics N V Ny Registry (STM)
Regeneron Pharmaceuticals (REGN)
EQT Corporation (EQT)

View all positions for Woodline Partners

Top funds holding Oruka Therapeutics

Fairmount Funds Management
VR Adviser
Commodore Capital
Perceptive Advisors
Avidity Partners Management
Franklin Resources
Paradigm Biocapital Advisors
Braidwell
Dr. Jeffrey R. Jay, M.D.
Point72 Asset Management
Frazier Life Sciences Management
Redmile Group
Woodline Partners
Affinity Asset Advisors
Driehaus Capital Management

View all funds holding Oruka Therapeutics